Floatz logo

INCOBOTULINUMTOXINA

Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury

Merz Therapeutics GmbHprotein_peptidePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury cohort.

Asset / SponsorPhaseRating
Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 4BB
Dfn-15
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 4BB
NEPENTHE
Nova Scotia Health Authority
Phase 4BB
Naltrexone
Emory University
Phase 4BB
FENTANYL
Cephalon
Phase 3B

View all 20 →

Same molecule, other indications

INCOBOTULINUMTOXINA is also rated in:

stroke disorderDormant
BBB
Indicative ·
78 / 100
View asset →
Muscle SpasticityDormant
BB
Indicative ·
69 / 100
View asset →
Parkinson diseaseDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →